Skip to content
Research Article Open access CC BY 4.0

The Therapeutic Potential of Cannabidiol in Parkinson's Disease: A Review of Mechanisms of Action and Clinical Effects

Isabelle Nunes Shimith da Silva, Sophia Souza Campos Nascente de Castro, Pedro Lucas Enomoto Lima, Maykon Jhuly Martins de Paiva

International Neuropsychiatric Disease Journal · pp. 45–54 · Published 16 Aug 2024

10.9734/indj/2024/v21i5448

Abstract

Aims: This study aims to investigate the potential therapeutic effects and mechanisms of cannabidiol (CBD) in the treatment of Parkinson's disease (PD). Specifically, it focuses on understanding the role of CBD in managing motor and non-motor symptoms and its neuroprotective properties. Study Design: This research is a literature review. Place and Duration of Study: The study was conducted at the University of Gurupi, Paraíso do Tocantins, TO, in 2023. Methodology: A comprehensive literature review was conducted using databases such as Medline (PubMed), Biblioteca Virtual de Saúde (BVS), and Scientific Electronic Library Online (SciELO). Articles published in Portuguese and English were included. The search terms used were "Parkinson's Disease," "CBD," and "Treatment." The selection criteria focused on studies exploring the mechanisms of action, anti-inflammatory, and analgesic properties of CBD in the context of PD. Articles unrelated to the use of CBD for PD treatment or not exclusively focusing on CBD administration were excluded. Results: The review included findings from seven scientific articles. Key outcomes indicate that CBD exhibits neuroprotective effects, reduces global symptom scores, and does not produce adverse motor effects. Notably, CBD was found to protect against cell death induced by neurotoxins like MPP+ and provide potential anti-inflammatory benefits by modulating cytokine release. Conclusion: CBD shows promise as a therapeutic agent in PD due to its neuroprotective, anti-inflammatory, and analgesic properties. However, the clinical use of CBD remains limited and controversial, requiring further research to validate its efficacy and safety in treating PD. This summary provides an overview of the findings and methodologies covered in the full text, highlighting the potential and challenges of using CBD in Parkinson's disease treatment.

Cannabidiol (CBD) parkinson's disease neuroprotection anti-inflammatory effects motor symptoms

References (25)

  1. 1 An Introduction to the Endogenous Cannabinoid System [DOI]
  2. 2 Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease [DOI]
  3. 3 CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity [DOI]
  4. 4 Oxidative Stress in Neurodegenerative Diseases [DOI]
  5. 5 The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis [DOI]
  6. 6 Cannabidiol: An Overview of Some Pharmacological Aspects [DOI]
  7. 7 Levodopa motor complications in Parkinson's disease [DOI]
  8. 8 Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial [DOI]
  9. 9 Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease [DOI]
  10. 10 Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial [DOI]
  11. 11 Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease [DOI]
  12. 12 Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease [DOI]
  13. 13 Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study [DOI]
  14. 14 Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease [DOI]
  15. 15 The Neurotherapeutic Arsenal in Cannabis sativa: Insights into Anti-Neuroinflammatory and Neuroprotective Activity and Potential Entourage Effects [DOI]
  16. 16 The Brain as a Target for Inflammatory Processes and Neuroprotective Strategies [DOI]
  17. 17 Cannabinoids and cell fate [DOI]
  18. 18 A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death [DOI]
  19. 19 1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide [DOI]
  20. 20 Cannabinoids: Between Neuroprotection and Neurotoxicity [DOI]
  21. 21 Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: Possible mechanism of action [DOI]
  22. 22 Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson's disease [DOI]
  23. 23 Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro [DOI]
  24. 24 Biological bases for a possible effect of cannabidiol in Parkinson’s disease [DOI]
  25. 25 Non-Motor Symptoms of Parkinson's Disease [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

48

Page views

0

PDF downloads

7

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.